Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JSKN016 versus investigator's choice therapy in previously treated advanced triple-negative breast cancer
CTR20260814Phase 3Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of JSKN016 in triple-negative breast cancer (TNBC), sponsored by Kanion Pharmaceutical. Primary endpoints: Progression-free survival and Overall survival. Started Mar 2026; status: active.
02
Drugs
JSKN016
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20260814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260814.